top of page
The Professional Network for Healthcare Experts
argenx agrees to acquire Forte Biosciences for approximately $2.2 billion
The acquisition gives argenx full ownership of FB102, expanding its immunology pipeline with a first-in-class anti-CD122 antibody that has shown early clinical proof of concept in autoimmune disease.
nuaxia
Jul 282 min read
Forte Biosciences Reports Positive Phase Ib Results for FB102 Vitiligo Treatment
The anti-CD122 monoclonal antibody demonstrated significant improvements in facial vitiligo scores, with results supporting further clinical development in autoimmune dermatology.
nuaxia
Jul 103 min read
bottom of page